Gendius, a UK-based diabetes research company, is set to close its equity crowdfunding campaign on Crowdcube with more than £475,000 in funding from nearly 385 investors. The campaign was launched earlier this summer and quickly raised its initial £400,000 funding target.
As previously reported, Gendius launched the campaign to raise the funds for to develop intellin, which is an app that takes an individual’s clinical history and tells them their risk of developing complications from their diabetes and how to manage these. The company further explained:
“Our mission is to ensure that every person with diabetes understands their risk of complications and how to manage them. The NHS alone spends over £11 billion a year on diabetes & 80% of these costs are avoidable and linked to the complications. The personal impact of diabetes is huge with the disease leading to; blindness, kidney failure, amputation, heart attack and/or stroke. The number of adults living with diabetes has almost quadrupled since 1980 to 422 million adults and this will reach 629 million by 2045. We have a B2B2C offering where we will access the NHS via the NHS app store and through pilots with GP practices. The B2C offering will be via a monthly charge on the app stores.”
It was also revealed that intellin will gather personal and disease-specific information that enables the program to identify the user’s personal areas of risk. The campaign’s funds will be used to continue the growth and development of intellin.
Through the campaign, Gendius is offering 14.80% in equity at a £2,500,000 pre-money valuation. The funding round is set to close this weekend.
Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!